Showing results (41-50 of 81) with videos related to
Sort By:
Pageof 9
The Journal of Clinical Endocrinology and Metabolism|December 22, 2022
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice GuidelineGhada El-Hajj Fuleihan, Gregory A Clines, Mimi I Hu, et al.Clinical Breast Cancer|November 26, 2013
A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancerRyan P Roop, Michael J Naughton, Catherine Van Poznak, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancerMonica N Fornier, Andrew D Seidman, Diana Lake, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2019
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System MetastasesAki Morikawa, Elisa de Stanchina, Elena Pentsova, et al.JAMA Oncology|January 27, 2017
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical TrialGabriel N Hortobagyi, Catherine Van Poznak, W Graydon Harker, et al.Journal of the National Cancer Institute|August 21, 2013
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNAJames M Rae, Meredith M Regan, Jacklyn N Thibert, et al.Oncotarget|May 26, 2016
Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patientsGladys Morrison, Divya Lenkala, Bonnie LaCroix, et al.Cancer Investigation|October 6, 2005
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi, Michael P DiGiovanna, Zhao Lu, et al.Oral Diseases|December 4, 2020
Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancerCatherine Van Poznak, Evan L Reynolds, Cherry L Estilo, et al.Radiation Oncology (London, England)|August 23, 2013
Concurrent whole brain radiotherapy and bortezomib for brain metastasisChristopher D Lao, Judah Friedman, Christina I Tsien, et al.Pageof 9